AGAT deficiency is a very rare inherited disease that blocks the first step of the body’s creatine-making pathway. The AGAT enzyme (made by the GATM gene) normally joins the amino acids arginine and glycine to form guanidinoacetate (GAA), which is then turned into creatine. Creatine is a small energy “buffer” used by the brain and muscles to power quick work. When AGAT is missing or very weak, GAA and creatine are both low—especially in the brain. The main results are delayed development, learning problems, speech delay, and sometimes muscle weakness or seizures. Giving oral creatine monohydrate early can improve symptoms because it supplies the missing fuel directly. The condition is autosomal recessive, meaning a child must inherit a faulty GATM copy from each parent. NCBIMedlinePlusNational Organization for Rare Disorders

---

Other names

AGAT deficiency is also called GATM deficiency, L-arginine:glycine amidinotransferase deficiency, creatine biosynthesis disorder type 2, and is grouped under the cerebral creatine deficiency syndromes (CCDS) along with GAMT deficiency and creatine transporter (CRTR) deficiency. Older literature may use “cerebral creatine deficiency syndrome 3,” reflecting its place in the CCDS group. All names point to the same disorder: a shortage of creatine in the brain caused by failure of the first creatine-synthesis enzyme. NCBINational Organization for Rare Disorders

---

Types

There are no official medical subtypes, but clinicians often find these practical groupings helpful:

1) Classic neurodevelopmental-predominant AGAT deficiency.
Children show global developmental delay, speech-language delay, and learning problems. Behavior differences (including autistic features) can appear. Seizures may occur. Brain MR spectroscopy shows low or absent creatine. MedlinePlusNCBI

2) Myopathy-predominant AGAT deficiency.
Some patients mainly have low muscle tone and weakness (a treatable myopathy), with variable cognitive impact. Creatine supplementation can improve strength. Orpha.netScienceDirect

3) Early-detected/presymptomatic AGAT deficiency.
Found through family testing or broad genetic panels; early creatine therapy can prevent or greatly lessen symptoms. PubMed

---

Causes

Important note: The only true root cause is pathogenic variants in the GATM gene that cripple AGAT enzyme activity. Items below explain the different genetic mechanisms and real-world contributors that lead to or influence the disease course.

1. Biallelic GATM mutations (autosomal recessive). Two harmful variants—one from each parent—are required for disease. NCBI

2. Missense variants in GATM. A single amino-acid change that reduces enzyme function. ScienceDirect

3. Nonsense variants. Premature stop signals that truncate the protein. ScienceDirect

4. Frameshift variants. Small insertions/deletions that scramble the protein code. ScienceDirect

5. Splice-site variants. Errors that disrupt proper RNA splicing and enzyme production. ScienceDirect

6. Exonic deletions/duplications of GATM. Copy-number changes that remove or add gene segments. NCBI

7. Founder variants. Recurrent mutations within specific populations or families. (Reported in CCDS in general; AGAT cases are extremely rare.) actionability.clinicalgenome.org

8. Consanguinity (parents related by blood). Increases the chance both carry the same rare variant. actionability.clinicalgenome.org

9. Compound heterozygosity. Two different harmful variants—one on each parental copy—produce disease. NCBI

10. Loss-of-function burden in GATM. Any combination of variants that drive enzyme activity near zero. ScienceDirect

11. Regulatory/promoter variants (rare). Changes that lower GATM expression. (Mechanism recognized for many metabolic genes; rare in AGAT due to few cases.) ScienceDirect

12. Unreported ultra-rare variants. Novel changes found on sequencing that prove pathogenic by biochemical evidence (very low GAA/creatine and absent brain MRS creatine). Nature

Modifiers that do not cause the disease but can worsen expression if untreated:

13. Late diagnosis (delayed start of creatine therapy) allows deficits to accumulate. PubMed

14. Poor adherence to creatine supplementation. Leads to persistent brain creatine shortage. NCBI

15. Intercurrent illness/fever raising energy needs, sometimes precipitating seizures. MedlinePlus

16. Very low dietary creatine intake (e.g., strict vegan diet) does not cause AGAT deficiency but can further limit the already low creatine pool until treatment begins. NCBI

17. High growth demand in infancy/childhood, which increases brain energy needs and reveals deficits. NCBI

18. Coexisting neuromuscular stress (e.g., deconditioning), which can exaggerate weakness. Orpha.net

19. Other genetic background factors that affect creatine handling or neuronal energy metabolism (inference from CCDS literature). PMC

20. Delayed access to specialty care or diagnostic testing, prolonging undiagnosed creatine deficiency. SpringerOpen

---

Symptoms

1. Global developmental delay. Children reach milestones (sitting, standing, talking) later than peers because the brain has less creatine available for fast energy. MedlinePlus

2. Intellectual disability or learning problems. Thinking and school skills are below age level; severity varies. National Organization for Rare Disorders

3. Expressive speech-language delay. Children understand more than they can say; words come late and sentences are short. MedlinePlus

4. Autism-spectrum-like behaviors. Social communication differences and repetitive behaviors can appear. MedlinePlus

5. Seizures (sometimes febrile). Electric storms in the brain may start with fever or illness. Not all patients have seizures. MedlinePlus

6. Low muscle tone (hypotonia). The body feels floppy; joints move easily; posture control is hard. Orpha.net

7. Muscle weakness / myopathy. Climbing stairs, running, or lifting can be difficult; fatigue comes early. ScienceDirect

8. Delayed motor milestones. Sitting, crawling, and walking are later than expected. GARD Information Center

9. Behavioral challenges. Attention problems, irritability, or hyperactivity can occur. National Organization for Rare Disorders

10. Poor weight gain or “failure to thrive” in some. Extra energy strain without enough creatine support. GARD Information Center

11. Coordination problems. Fine motor tasks (buttons, drawing) and balance can be hard. National Organization for Rare Disorders

12. Fatigability. Tiring faster during play or therapy sessions because quick energy buffering is low. NCBI

13. Headaches in older children (less common; may be related to energy stress). PMC

14. Normal appearance between episodes. Many children look well but struggle with skills that require fast brain energy. NCBI

15. Improvement after starting creatine. Over months, speech and strength may improve, especially if therapy starts early. NCBIPMC

---

Diagnostic tests

A) Physical examination (bedside assessment)

1. General growth check (weight, length/height, head size). Screens for failure to thrive or disproportion that may suggest broader metabolic issues; most AGAT cases have normal growth but poor weight gain can occur. GARD Information Center

2. Neurologic tone exam. Detects hypotonia by checking limb resistance and posture. Supports suspicion of energy-related myopathy. Orpha.net

3. Strength and endurance observation. Standing from floor, stair climbing, and timed up-and-go reveal weak, easily tired muscles. ScienceDirect

4. Developmental screening. Standard tools (e.g., simple milestone checklists) identify delays in language, problem-solving, and motor skills. MedlinePlus

5. Behavioral/ASD screening. Quick questionnaires flag social-communication differences common across CCDS. National Organization for Rare Disorders

B) Manual/functional tests (clinic-based performance)

6. Fine-motor tasks (grip, peg tests). Practical measures of hand coordination impacted by low brain energy buffering. National Organization for Rare Disorders

7. Gait and balance assessment. Heel-toe walking or Romberg stance can show balance instability in motor-delayed children. National Organization for Rare Disorders

8. Speech-language evaluation. Structured play and naming tasks quantify expressive delay and guide therapy plans. MedlinePlus

9. Cognitive/developmental testing. Age-appropriate standardized tests define learning profile and track response to creatine therapy. PMC

10. Six-minute walk or submaximal endurance tasks (when age-appropriate). Track fatigability and change after supplementation. ScienceDirect

C) Laboratory and pathological tests (key for diagnosis)

11. Plasma or urine guanidinoacetate (GAA). Characteristic finding in AGAT deficiency is very low or almost undetectable GAA, unlike GAMT deficiency (high GAA). This is a top screening test. Nature

12. Plasma/urine creatine and creatinine. Often low-normal to low; urine creatine/creatinine ratio may be altered, supporting creatine shortage. Results are interpreted with GAA and clinical signs. Nature

13. Amino acid profile (arginine/ornithine). Helps exclude other urea-cycle or metabolic issues and documents substrate status; not diagnostic alone. NCBI

14. Creatine response trial (therapeutic monitoring). After starting oral creatine monohydrate, rising blood/urine creatine and clinical gains support the diagnosis while genetic confirmation is pending. NCBI

15. Molecular genetic testing of GATM. Sequencing and copy-number analysis confirm biallelic pathogenic variants, the gold standard for diagnosis and family counseling. NCBI

D) Electrodiagnostic tests

16. EEG (electroencephalogram). Used if seizures occur; may be normal between events but can show epileptiform activity that guides seizure care. MedlinePlus

17. EMG/nerve conduction studies (if prominent weakness). Reveal a myopathic pattern when muscle involvement is significant; nerves are usually normal. ScienceDirect

E) Imaging tests

18. Brain MRI. Often structurally normal or nonspecific; used to rule out other brain diseases. PubMed

19. Brain MR spectroscopy (MRS). Signature test: the creatine peak at ~3.0 ppm is reduced or absent in untreated AGAT deficiency; this finding, together with low GAA, strongly points to AGAT/GAMT deficiency before genetics returns. PubMed

20. Muscle MRI (selected cases). May support a metabolic myopathy picture and track recovery with creatine therapy. Not required for diagnosis but can be helpful when weakness dominates. ScienceDirect

Non-pharmacological treatments

Physiotherapy & Rehab

1. Early gross-motor physiotherapy
   Description. A therapist teaches simple play-based moves to build rolling, sitting, crawling, standing, and walking. Sessions are short, frequent, and fun, with home practice.
   Purpose. Improve motor milestones and reduce delay.
   Mechanism. Repeated task practice drives neuroplasticity and strengthens neuromuscular pathways needed for posture and gait.
   Benefits. Faster motor progress, better balance and confidence; less caregiver stress.

2. Strength training with body weight
   Description. Simple, safe exercises (sit-to-stand, step-ups, wall push-ups) scaled to age.
   Purpose. Improve muscle force to counter myopathy.
   Mechanism. Progressive overload increases motor-unit recruitment and muscle protein synthesis.
   Benefits. Stronger legs and trunk; easier transfers, stairs, and longer walking.

3. Postural control and core stability
   Description. Trunk control drills on mats, therapy balls, and wobble boards.
   Purpose. Reduce slumping and fatigue; support speech and hand use.
   Mechanism. Activates deep trunk muscles; strengthens anticipatory postural responses.
   Benefits. Better endurance, safer mobility, and improved breath support for speech.

4. Balance and coordination training
   Description. Beam walks, obstacle courses, catching/throwing, rhythm and stepping games.
   Purpose. Improve steadiness and dual-task control.
   Mechanism. Cerebellar and vestibular challenge with graded sensory input refines motor timing.
   Benefits. Fewer falls, smoother movement transitions, more independent play.

5. Gait training
   Description. Practice walking on even/uneven surfaces, ramps, and in community settings; consider treadmill with supports.
   Purpose. Normalize gait pattern and endurance.
   Mechanism. High-repetition stepping builds central pattern generation and cardiorespiratory capacity.
   Benefits. Longer distances, less fatigue, safer outdoor mobility.

6. Stretching and range-of-motion program
   Description. Daily gentle stretches for calves, hamstrings, hips, and shoulders.
   Purpose. Prevent tightness due to hypotonia compensations.
   Mechanism. Maintains muscle-tendon length; reduces risk of contracture.
   Benefits. Easier dressing and walking; better comfort.

7. Functional electrical stimulation (FES) as needed
   Description. Low-level electrical pulses to help dorsiflexion or quadriceps during tasks.
   Purpose. Support weak muscles in training.
   Mechanism. Enhances motor learning via sensory-motor feedback and increased repetitions.
   Benefits. Clearer step patterns; may reduce need for braces in select cases.

8. Respiratory and orofacial therapy
   Description. Breathing games, blowing, bubble and straw tasks, and oromotor therapy with SLP/OT.
   Purpose. Improve breath support and safe chewing/swallowing.
   Mechanism. Strengthens diaphragmatic control; coordinates oral muscles.
   Benefits. Better speech clarity, safer feeding, less choking risk.

9. Occupational therapy for fine-motor skills
   Description. Hands-on work for grasp, release, tool use, and self-care routines.
   Purpose. Improve daily living (buttons, feeding, writing).
   Mechanism. Repetition of meaningful tasks builds motor maps and hand strength.
   Benefits. More independence at home and school.

10. Sensory integration approaches
    Description. Structured sensory play (textures, swings, deep pressure) when sensory processing issues exist.
    Purpose. Improve attention and regulation to support learning.
    Mechanism. Controlled sensory input modulates arousal systems.
    Benefits. Fewer meltdowns; better focus in therapy and class.

11. Orthotics and adaptive equipment
    Description. Foot orthoses/AFOs, seating supports, walkers as needed.
    Purpose. Optimize alignment and energy efficiency.
    Mechanism. External stabilization reduces compensatory strain.
    Benefits. Smoother walking; less fatigue; safer posture.

12. Hydrotherapy/aquatic therapy
    Description. Movement in warm water with buoyancy support.
    Purpose. Build strength and range with less joint load.
    Mechanism. Buoyancy + resistance enhances muscle activation safely.
    Benefits. High engagement, better endurance, low fall risk.

13. Energy-conservation pacing
    Description. Plan rests, alternate hard/easy tasks, and use wheeled mobility for long distances.
    Purpose. Prevent over-fatigue in myopathy.
    Mechanism. Matches activity demand to physiologic capacity.
    Benefits. More participation through the day.

14. Home exercise & caregiver coaching
    Description. Simple daily routines parents can run in minutes.
    Purpose. Keep gains between clinic visits.
    Mechanism. High frequency practice = stronger neuroplasticity.
    Benefits. Faster progress and better carryover.

15. Community/peer physical activity
    Description. Inclusive sports, dance, or martial arts with adapted rules.
    Purpose. Social motivation for long-term activity.
    Mechanism. Enjoyment and peer modeling sustain repetition.
    Benefits. Fitness, confidence, friendships.

Mind-Body, Genetics, and Educational Therapies

16. Speech-language therapy (expressive/receptive)
    Description. Focus on vocabulary, short phrases, and social language; lots of visuals.
    Purpose. Boost speech, which is commonly delayed.
    Mechanism. Repetition and modeling build neural language circuits.
    Benefits. Clearer communication and better school engagement. NCBI

17. AAC (augmentative and alternative communication)
    Description. Picture boards or speech-generating devices when speech is limited.
    Purpose. Give a reliable voice now while speech develops.
    Mechanism. Bypasses motor speech limits; supports language growth.
    Benefits. Less frustration; improved learning and behavior.

18. Applied behavior analysis (ABA) or behavior therapy as indicated
    Description. Individualized plans to shape attention, reduce problem behaviors, and teach daily skills.
    Purpose. Manage co-occurring behavior issues.
    Mechanism. Structured reinforcement and task analysis.
    Benefits. Better focus, safer behavior, smoother routines. NCBI

19. Parent-mediated early intervention
    Description. Train caregivers to deliver short, play-based learning every day.
    Purpose. Multiply therapy time.
    Mechanism. Frequent, consistent cues at home accelerate learning.
    Benefits. Faster language and motor gains.

20. Educational therapy and IEP planning
    Description. Special education with concrete, visual teaching, short instructions, and repetition.
    Purpose. Match teaching to cognitive profile.
    Mechanism. Scaffolding and spaced practice improve retention.
    Benefits. Better literacy, numeracy, and independence. NCBI

21. Occupational therapy for self-regulation
    Description. Routines for transitions, timers, and calm-down kits.
    Purpose. Reduce dysregulation that blocks learning.
    Mechanism. Behavioral and sensory strategies improve executive control.
    Benefits. Fewer outbursts; more time on task.

22. Sleep hygiene program
    Description. Regular bedtime, light control, quiet routine; treat snoring if present.
    Purpose. Support brain recovery and daytime attention.
    Mechanism. Stabilizes circadian rhythms and REM.
    Benefits. Better daytime focus and mood.

23. Mindfulness/mind-body relaxation (age-adapted)
    Description. Breathing games, guided imagery, kid yoga.
    Purpose. Lower stress and improve attention.
    Mechanism. Parasympathetic activation reduces arousal.
    Benefits. Improved coping and participation.

24. Genetic counseling for the family
    Description. Explain autosomal recessive inheritance, carrier status, and options for future pregnancies.
    Purpose. Informed planning and early testing in relatives at risk.
    Mechanism. Molecular information + counseling.
    Benefits. Earlier diagnosis and treatment in siblings. NCBI

25. Clinical follow-up with creatine therapy monitoring
    Description. Regular visits to check development, review adherence, and monitor kidneys while on creatine. Brain MRS may be repeated to confirm creatine repletion.
    Purpose. Keep therapy safe and effective long term.
    Mechanism. Surveillance detects side effects and guides dose.
    Benefits. Sustained gains with lower risk. NCBI

---

Drug treatments

1. Creatine monohydrate (core therapy; supplement but used as a “drug”)
   Class. Energy substrate replacement. Dose/Time. About 400–800 mg/kg/day by mouth, split into 3–6 doses; start early in life and continue long term; monitor kidneys yearly. Purpose. Refill brain and muscle creatine to support energy use and neurodevelopment. Mechanism. Increases intracellular creatine and phosphocreatine, improving ATP buffering in neurons and myocytes; restores the brain creatine peak on ¹H-MRS. Side effects. Usually mild (GI upset, weight gain/water retention); rare kidney strain—hence annual kidney checks. Evidence. In AGAT deficiency, creatine improves muscle weakness and helps language/cognition most when started before age ~2; late start (>10 years) may give limited cognitive change but still helps muscle. Notes. Do not add arginine restriction/ornithine for AGAT; that is a GAMT-specific strategy. NCBI+1Association for Creatine Deficiencies

2. Levetiracetam (only if seizures occur)
   Class. Antiseizure drug. Dose. Common pediatric start 10 mg/kg twice daily; titrate per specialist. Purpose. Control seizures if present (seizures are uncommon in AGAT, but may occur). Mechanism. Modulates synaptic vesicle protein 2A to reduce hypersynchronous firing. Side effects. Somnolence, irritability or mood change; rare behavioral issues. Evidence. AGAT deficiency itself rarely shows epilepsy; when it does, standard epilepsy care is recommended by guidelines for creatine deficiency disorders. NCBI

3. Lamotrigine (if seizures or mood instability)
   Class. Antiseizure/mood stabilizer. Dose. Slow titration per weight to reduce rash risk. Purpose. Alternative or add-on seizure control. Mechanism. Inhibits voltage-gated sodium channels; stabilizes neuronal membranes. Side effects. Rash (rarely serious), dizziness, GI upset. Evidence. Standard pediatric neurology practice for focal/generalized seizures; not AGAT-specific. NCBI

4. Clobazam
   Class. Benzodiazepine antiseizure. Dose. Per specialist; often used as add-on. Purpose. Help control breakthrough seizures. Mechanism. GABA-A positive allosteric modulation. Side effects. Sedation, drooling, tolerance. Evidence. Symptomatic use when indicated; not disease-modifying. NCBI

5. Valproate (use with caution)
   Class. Broad-spectrum antiseizure. Dose. Weight-based; monitor liver function. Purpose. Seizure control if others fail. Mechanism. GABAergic and sodium channel effects. Side effects. Weight gain, tremor, liver toxicity risk; avoid in certain metabolic settings and in pregnancy (teratogenic). Evidence. General epilepsy care; not AGAT-specific. NCBI

6. Melatonin
   Class. Sleep-regulating hormone (OTC in many countries). Dose. 1–5 mg at bedtime in children (local guidance varies). Purpose. Improve sleep onset and maintenance to support daytime learning. Mechanism. Circadian rhythm entrainment. Side effects. Morning sleepiness, vivid dreams. Evidence. Widely used in neurodevelopmental disorders for sleep issues; supportive, not disease-modifying. NCBI

7. Methylphenidate (if ADHD diagnosed)
   Class. CNS stimulant. Dose. Titrate under specialist care. Purpose. Improve attention and reduce hyperactivity/impulsivity. Mechanism. Inhibits dopamine/norepinephrine reuptake in prefrontal cortex. Side effects. Appetite loss, insomnia, irritability; monitor growth and BP. Evidence. GeneReviews notes standard behavioral and pharmacologic care for attention/behavior as needed. NCBI

8. Guanfacine (non-stimulant ADHD option)
   Class. Alpha-2A agonist. Dose. Weight- and formulation-specific. Purpose. Attention, impulsivity, and tics; can help sleep. Mechanism. Enhances prefrontal control circuits. Side effects. Sleepiness, low BP. Evidence. Standard pediatric behavioral care when appropriate. NCBI

9. Risperidone (for severe aggression or irritability)
   Class. Atypical antipsychotic. Dose. Low-dose start; careful monitoring. Purpose. Reduce dangerous aggression/self-injury that blocks learning. Mechanism. Dopamine/serotonin receptor modulation. Side effects. Weight gain, metabolic effects, sedation; monitor closely. Evidence. Used across neurodevelopmental conditions when needed; not AGAT-specific. NCBI

10. Baclofen (if spasticity emerges; many children have hypotonia)
    Class. Antispasticity agent. Dose. Low start, slow titrate. Purpose. Reduce tone and ease therapy. Mechanism. GABA-B agonism reduces spinal reflexes. Side effects. Sedation, weakness. Evidence. Symptom-driven; not disease-modifying. NCBI

11. Polyethylene glycol (PEG 3350)
    Class. Osmotic laxative. Dose. Per pediatric GI guidance. Purpose. Treat constipation that slows feeding and learning. Mechanism. Softens stool by water retention. Side effects. Gas, diarrhea if too much. Evidence. Supportive care standard.

12. Proton-pump inhibitor or H2 blocker (if reflux impairs feeding)
    Purpose. Reduce acid and pain to support nutrition. Mechanism. Acid suppression. Side effects. Rare with short use. Evidence. Supportive; improves feeding therapy tolerance.

13. Acetaminophen/ibuprofen (short-term)
    Purpose. Control pain or fever so therapy can continue. Mechanism. COX inhibition (ibuprofen) or central antipyretic (acetaminophen). Evidence. Symptomatic only; avoid chronic use without medical advice.

14. Topical fluoride/standard dental meds
    Purpose. Oral health to support feeding and speech. Mechanism. Enamel strengthening; reduces caries risk.
    Evidence. General pediatric standards.

15. Vaccines (per schedule)
    Class. Immunizations (not a “drug therapy” for AGAT itself but essential health care). Purpose. Prevent infections that interrupt therapy and nutrition. Mechanism. Active immunity. Side effects. Usual minor reactions. Evidence. Universal pediatric recommendation.

Important note: Beyond creatine, no medicine is proven to fix the enzyme block in AGAT deficiency. Other drugs are only for symptoms or co-morbid issues, as recommended by your clinicians. NCBI

---

Dietary molecular supplements

1. Creatine monohydrate (core; see above)
   Dose. 400–800 mg/kg/day in divided doses. Function/Mechanism. Restores brain/muscle creatine and phosphocreatine, supporting ATP buffering and synaptic function. Notes. Annual kidney checks; start early for best outcomes. NCBI

2. Omega-3 DHA/EPA
   Dose. Typical pediatric DHA 100–250 mg/day (product-dependent). Function. Structural brain lipids; support synapse and anti-inflammatory signaling. Mechanism. Membrane fluidity and signaling mediators. Notes. May help attention in some children; quality-controlled products only.

3. Vitamin D
   Dose. As per local pediatric guidance (often 400–1000 IU/day). Function. Bone health, immune regulation, and possible neurotrophic effects. Mechanism. Nuclear receptor signaling affecting gene transcription. Notes. Check levels; avoid excess.

4. Iron (if deficient)
   Dose. Weight-based elemental iron under clinician guidance. Function. Hemoglobin and neuronal myelination; deficiency harms cognition. Mechanism. Oxygen transport and enzyme co-factors. Notes. Only if labs show deficiency; can upset stomach.

5. Zinc (if low)
   Dose. Age-appropriate RDA; treat deficiency per labs. Function. Synaptic function and immune health. Mechanism. Cofactor in many enzymes; modulates neurotransmission. Notes. Too much can lower copper.

6. Vitamin B12/folate (if low)
   Dose. Correct deficiencies per labs. Function. One-carbon metabolism and myelin. Mechanism. Methylation reactions important for brain development. Notes. Screen before supplementing.

7. Magnesium
   Dose. Dietary intake to RDA; supplements only if advised. Function. NMDA receptor modulation and muscle/nerve function. Mechanism. Co-factor in ATP reactions. Notes. Can loosen stools.

8. Protein adequacy
   Dose. Meet age-based protein needs; do not do arginine restriction in AGAT deficiency. Function. Growth and muscle repair. Mechanism. Supplies amino acids for tissue building. Notes. Arginine restriction is a GAMT-only strategy; it is not recommended for AGAT. NCBIAssociation for Creatine Deficiencies

9. Fiber and hydration
   Function. Gut health and regular stools to support feeding and comfort. Mechanism. Stool bulk and microbiome support. Notes. Use fruits, vegetables, whole grains, and fluids.

10. General micronutrient multivitamin
    Function. Backstop for picky eating. Mechanism. Ensures RDAs for brain growth. Notes. Avoid mega-doses.

---

Immunity booster / regenerative / stem-cell” drugs

There are no approved immune-booster, regenerative, or stem-cell drugs that treat AGAT deficiency. Using such products outside a regulated clinical trial can be harmful or fraudulent. Below I explain safer alternatives and what research exists:

1. Stem cell therapy – Not indicated. No evidence it corrects GATM enzyme loss; not recommended.

2. “Creatine ethyl ester” or exotic creatine salts – Not superior. Standard creatine monohydrate is best-studied; stick with it.

3. Cyclocreatine / creatine esters – Experimental. Animal or transporter-defect research; not AGAT-approved. NCBI

4. AAV-based gene therapy to deliver GATM – Conceptual only. No approved human therapy; any offer outside trials should be refused.

5. High-dose “immune boosters” – Avoid. Mega-doses of vitamins/herbals can harm the liver/kidney.

6. What to do instead – Keep vaccines up to date, maintain sleep, nutrition, physical activity, and take creatine as prescribed; these have real evidence and safety. NCBI

---

Surgeries

AGAT deficiency itself does not require surgery. But if co-morbid issues arise, surgeons may help:

1. Strabismus surgery (if significant eye misalignment affects vision).
   Procedure. Adjust extraocular muscles to align eyes.
   Why. Improve binocular vision and reduce eye strain.

2. Gastrostomy tube (if severe oral feeding failure with poor weight gain).
   Procedure. Place a small tube into the stomach for nutrition.
   Why. Ensure safe and adequate calories while therapy continues.

3. Tendon-lengthening (if fixed contractures ever develop).
   Procedure. Lengthen tight tendons.
   Why. Improve range and ease of care.

4. Scoliosis correction (only if progressive spinal curve causes pain or function limits).
   Procedure. Bracing first; surgery for severe curves.
   Why. Pain relief and postural stability.

5. Adenotonsillectomy (if sleep apnea documented).
   Procedure. Remove enlarged tonsils/adenoids.
   Why. Better sleep to aid learning.

These surgeries are not routine in AGAT deficiency; they are case-by-case based on standard pediatric indications.

---

Preventions / health-protection steps

1. Start creatine early once diagnosed; earlier treatment gives better cognitive outcomes. NCBI

2. Take the full daily dose split during the day; set reminders. NCBI

3. Yearly kidney checks (e.g., GFR/creatinine) while on chronic creatine. NCBI

4. No arginine/protein restriction for AGAT deficiency (that applies to GAMT, not AGAT). NCBIAssociation for Creatine Deficiencies

5. Monitor development at each visit; adjust therapy intensity. NCBI

6. Keep vaccines current to prevent illness interruptions.

7. Protect sleep and treat snoring.

8. Ensure nutrition and hydration for energy and bowel health.

9. Share the diagnosis at school to secure an IEP and supports. NCBI

10. Genetic counseling for family planning and testing at-risk siblings. NCBI

---

When to see doctors urgently or soon

• New or worsening seizures, loss of skills, sudden severe headache, or concerning behavior changes → urgent care. NCBI

• Trouble breathing, repeated choking, dehydration, or poor weight gain → urgent evaluation.

• Persistent vomiting, new severe fatigue, or swelling while on creatine → check labs and kidney function. NCBI

• Any regression in language or motor skills → prompt re-assessment of therapy plan and adherence.

---

What to eat” and “what to avoid”

Eat more of:

1. Balanced meals with whole foods and adequate protein for age.

2. Fruits/vegetables for vitamins, minerals, fiber.

3. Whole grains/legumes for steady energy and fiber.

4. Healthy fats (olive oil, nuts, seeds) and omega-3 sources (fish) for brain health.

5. Fluids across the day to support kidneys and bowel.

Avoid or limit:

1. Crash or restrictive diets (especially arginine/protein restriction)—not for AGAT deficiency. NCBIAssociation for Creatine Deficiencies
2. Ultra-processed, very salty foods that may stress kidneys when fluid intake is poor.
3. Excess caffeine/energy drinks in teens (sleep disruption).
4. Large megadose supplements or “immune boosters” without labs/medical advice.
5. Alcohol and vaping in older teens—harms brain development.

---

Frequently asked questions (FAQs)

1. Is AGAT deficiency treatable?
   Yes. Creatine monohydrate by mouth is the key therapy; early treatment gives the best results. NCBI

2. What dose of creatine is used?
   About 400–800 mg/kg/day in 3–6 doses; your clinician will personalize it. NCBI

3. Will my child’s language improve?
   Language can improve, especially when creatine starts in infancy plus speech and education therapies. Starting after ~10 years may help muscles more than cognition. NCBI

4. Do we need a special low-arginine diet?
   No—that is for GAMT deficiency, not AGAT deficiency. Diet restriction is not typically recommended for AGAT. NCBIAssociation for Creatine Deficiencies

5. How is AGAT deficiency diagnosed?
   By low brain creatine on ¹H-MRS, very low GAA in blood/urine, and GATM gene testing. NCBIPMC

6. Is epilepsy common?
   Not usually; among reported AGAT cases, seizures are rare compared to other creatine disorders. Standard care is used if seizures occur. NCBI+1

7. How rare is it?
   Extremely rare; only a small number of cases have been reported worldwide. Metabolic Support UK

8. Is creatine safe long term?
   Generally well-tolerated; yearly kidney checks are recommended during chronic use. NCBI

9. Does creatine fix the gene?
   No. It replaces the missing product (creatine). The gene change remains. NCBI

10. Are stem-cell or gene therapies available?
    No approved treatments yet for AGAT deficiency; avoid unregulated offers. NCBI

11. Should siblings be tested?
    Yes—biochemical and/or genetic testing can allow early diagnosis and early creatine treatment if needed. NCBI

12. What specialists are involved?
    Metabolic/genetics, neurology, rehab (PT/OT/SLP), developmental pediatrics, and dietetics. NCBI

13. How will school help?
    With an IEP using visual supports, short steps, and repetition—plus speech/OT/PT as needed. NCBI

14. What monitoring is needed?
    Developmental checks each visit; annual kidney tests; sometimes repeat ¹H-MRS to confirm brain creatine restoration. NCBI

15. Where can we learn more or join research?
    GeneReviews (clinical overview), NORD and Orphanet (patient-friendly), and centers studying cerebral creatine deficiency. NCBINational Organization for Rare DisordersOrpha.netmedicine.utah.edu

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 10, 2025.